Doral

Quick links to important sections

Doral

Treatment option: Insomnia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Doral

Property Description
Active ingredient Quazepam
Form Tablet
Pharmacological class Sedative/Hypnotic, Benzodiazepine derivative
General purpose Temporary support for sleeplessness
Origin Synthetic molecule

The Identity of Doral: Composition and Origin

Doral is the brand name for the pharmaceutical preparation containing the active ingredient quazepam, a synthetic compound classified as a benzodiazepine derivative. This single-ingredient product is formulated for oral administration in the form of a tablet, functioning as a central nervous system (CNS) depressant. The chemical composition is specifically identified as a trifluoroethyl benzodiazepine, a structural feature that differentiates it within its class. The final tablet formulation uses common solid pharmaceutical excipients necessary for the product's stability and proper ingestion.


Doral's Pharmacological Class and General Purpose

Doral is formally categorized within the sedative/hypnotic pharmacological class, placing it among agents used to promote sleep onset and maintenance. This classification confirms the primary therapeutic intention of the compound is to induce a state of quietude. Pharmacological studies have consistently supported the efficacy of this classification for agents intended for the short-term management of insomnia.

The general purpose of Doral is to provide temporary support by addressing the issue of sleeplessness. Its fundamental action is linked to the primary inhibitory chemical messenger in the brain, Gamma-aminobutyric acid (GABA); the drug operates by acting as a positive allosteric modulator, which enhances the natural calming signals of GABA to reduce overall neuronal excitability and facilitate sleep. The drug is indicated for the treatment of insomnia, establishing it as a method to help quiet the brain for sleep.


Key Difference: Long-Acting Benzodiazepine Profile

While sharing the core benzodiazepine mechanism, quazepam is characterized by a relatively long-acting profile compared to other related compounds used for similar purposes. This difference in action is influenced by the fact that the administered compound, in addition to the parent drug, generates two major active metabolites—specifically, 2-oxoquazepam and N-desalkyl-2-oxoquazepam—which remain biologically active and contribute to the overall therapeutic effect over time. This prolonged activity is a key identifying characteristic of the substance, influencing its therapeutic application when a sustained effect is medically recognized as beneficial.

Regulatory References

  1. Quazepam (oral route) - MedlinePlus Drug Information

What side effects are possible with Doral?

Possible Side Effects and Safety Information

The official safety profile for Doral (quazepam) is fundamentally shaped by its classification as a central nervous system (CNS) depressant. The adverse reactions are classified primarily by frequency and the organ systems affected, as documented in regulatory labeling.


Documented Adverse Reactions and Frequencies

Adverse reactions that are common (occurring in 1% to 10% of individuals) include drowsiness (which may be mathbfvery common and persist into the next day), headache, fatigue, dizziness, dry mouth (xerostomia), and dyspepsia (indigestion). The primary physiological impact is noted across Nervous System Disorders and Gastrointestinal Disorders.


Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights serious adverse reactions, including complex sleep-related behaviors, such as sleep driving or cooking while not fully awake, with no memory of the event. Severe hypersensitivity reactions, such as mathbfanaphylaxis or angioedema, are also documented.

Abuse, Misuse, and Dependence: Continued use is associated with the risk of developing physical dependence and subsequent withdrawal reactions, which can be severe, including mathbfseizures, upon abrupt cessation. There is also a specific, high-level constraint documented regarding co-administration with mathbfopioid analgesics or other CNS depressants, noting the risk of mathbfprofound sedation, mathbfrespiratory depression, mathbfcoma, and mathbfdeath.


Population-Specific Safety Notes

Safety considerations apply to certain groups. Older adults are at a heightened risk of falls and injury due to the medication’s sedative effects. Use during mathbflate pregnancy carries an official risk of mathbfneonatal sedation and a mathbfwithdrawal syndrome in the newborn. The medicine is formally contraindicated in individuals with known sleep apnea or significant pulmonary insufficiency.

Overdose and Emergency Response

The official regulatory profile for Quazepam (Doral) overdose describes a dose-related spectrum of effects rooted in Central Nervous System (CNS) depression. Manifestations typically range from less severe signs like drowsiness, confusion, lethargy, and changes in speech patterns, to more profound clinical presentations such as loss of consciousness and impaired balance.

The primary severe outcomes documented include respiratory depression, coma, and ultimately, death. Regulatory information emphasizes that the risk of profound sedation and these life-threatening events is significantly increased when Quazepam is co-ingested with opioids or other CNS depressants.

Immediate medical attention or emergency treatment right away is required upon suspicion of overdose. Urgent help must be sought for label-defined critical signs, specifically slow or shallow breathing, cessation of breathing, or excessive sleepiness (sedation). The label directs users to call emergency services (e.g., 911) for these symptoms.

Overdose management involves general symptomatic and supportive treatment. The antagonist Flumazenil is available for reversal, but regulatory labels carry a documented warning that its administration may precipitate acute withdrawal reactions, including seizures. Elderly or debilitated patients are noted to have increased sensitivity to the depressant effects, placing them at a higher risk of adverse outcomes.

Therapeutic Uses of Doral

The medication Quazepam is commonly used to provide symptomatic support for the treatment of insomnia. Its therapeutic scope involves addressing three main symptom clusters: difficulty falling asleep, frequent nocturnal awakenings, and early morning waking. It is applied across domains where short-term symptom management is appropriate, relevant for patients experiencing both acute episodes of severe sleep loss and established chronic difficulties with the sleep-wake cycle. The therapeutic benefit assists with the transition into the sleep state, which is commonly associated with reduced sleep latency, and may assist with general well-being during symptomatic phases.

“The medication's sustained support contributes to easing the overall symptom load by supporting an increase in total sleep duration and helping improve the perceived quality of rest.”

Its use may offer temporary assistance, providing support that helps maintain a sense of stability during challenging symptomatic phases.


Quick Fact: Symptomatic support is provided for sleep maintenance issues.

Eligibility and Restrictions for Use

Official Population Eligibility and Restrictions

The eligibility profile for Doral (quazepam) is strictly defined by regulatory contraindications and population-specific limitations.

Mandatory Exclusions

Use is contraindicated for individuals with a known hypersensitivity to quazepam or other benzodiazepines. The medicine must also not be used in patients with established or suspected sleep apnea, pulmonary insufficiency, or a history of severe past reactions like angioedema or anaphylaxis after previous Doral use. Doral is contraindicated during pregnancy.

Restricted or Conditional Use

The medicine is approved for the adult population, but safety and effectiveness have not been established in pediatric patients.

Use in older adults requires caution due to a potential for increased sensitivity. Caution and close monitoring are also necessary for patients with impaired hepatic or renal function, as safety and efficacy are not established in these specific populations. Additionally, use is generally not recommended for nursing mothers, and caution is required for individuals with a history of alcohol or drug dependence or depression.

What should I know about interactions with other medicines?

Interactions with Central Nervous System Depressants

The official interaction profile for Doral (quazepam) is primarily defined by the risk of pharmacodynamic reinforcement with other substances that cause central nervous system (CNS) depression. Co-administration with opioid medicines carries a formal regulatory warning due to the potential for profound sedation, respiratory depression, coma, and death resulting from additive CNS depressant effects. This additive effect is documented to occur with other classes of CNS depressants as well, including other benzodiazepines and tricyclic antidepressants. The use of Doral with other sedative-hypnotic medicines is explicitly not recommended.

Substance and Timing Restrictions

Alcohol generally should not be used concurrently because of the documented risk of enhanced CNS depression and the potential for complex sleep behaviors. A timing constraint is formally noted in regulatory labeling: the risk of next-day psychomotor impairment is increased if Doral is taken when less than a full night of sleep (seven to eight hours) remains. The potential for adverse interactions continues for several days following discontinuation of Doral until the long-acting metabolites decline.

Metabolism-Mediated Effects

The medicine is subject to metabolism-mediated interactions in the liver. Co-administered agents that inhibit certain enzymes (such as CYP3A4) may decrease the metabolism of Doral, which may increase its plasma concentration and the potential for toxicity. Conversely, enzyme-inducing agents, including certain herbal products such as St John's Wort, may decrease Doral exposure by affecting its rate of metabolism.

Mechanism of Action

Doral (quazepam) functions as a positive allosteric modulator at the GABA A receptor complex, primarily within the central nervous system. The drug and its major active metabolite, 2-oxoquazepam, exhibit selective affinity for the benzodiazepine binding site located at the interface of the alpha and gamma subunits, with a unique preference for alpha1-containing GABA A receptors. This selective interaction increases the affinity of the receptor for the inhibitory neurotransmitter GABA.

Consequently, the frequency of chloride ion channel opening is enhanced upon GABA binding. The resulting surge of negative chloride ions into the post-synaptic neuron causes hyperpolarization of the neuronal membrane. This intracellular event reduces overall neuronal excitability and diminishes the transmission of action potentials. At a system level, this leads to a general dampening of central nervous system activity, modulating electrophysiological patterns associated with arousal.

Dosage and Administration Information

Doral (quazepam) is a medication for oral administration in the form of a 15 mg tablet. The approved administration schedule is strictly once per day, taken at bedtime.


Dosing Regimen

The recommended initial dose for most adults is 7.5 mg. The available 15 mg tablet is functionally scored, allowing for the 7.5 mg dose to be achieved by splitting the tablet along the score line. The usual daily dosing range is 7.5 mg to 15 mg, with the maximum dose not exceeding 15 mg per day.


Administration Context and Adjustments

Proper use requires taking the dose immediately before going to bed and only when the schedule permits a timeframe that guarantees a full night’s sleep of approximately seven to eight hours. For elderly or debilitated patients, treatment should be initiated at the lower end of the dosing range, typically 7.5 mg. The safety and effectiveness of quazepam have not been established for pediatric patients.


Duration and Discontinuation

The medication is intended for short-term administration, and prolonged use is generally not recommended. Consistent with usage protocols for this class of medicine, discontinuation or dosage reduction requires a gradual taper to ensure the medication is stopped properly.

Recent Clinical Evidence

Doral: Recent Clinical Evidence

Doral (quazepam) is a long-acting benzodiazepine indicated for the treatment of insomnia characterized by difficulties with falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The medication is a central nervous system (CNS) depressant.

Clinical Efficacy and Study Findings

Clinical studies have established the effect of quazepam in managing both sleep induction (time needed to fall asleep) and sleep maintenance (reducing wake time after sleep onset and increasing total sleep time).

  • Acute Insomnia: Efficacy was demonstrated in placebo-controlled studies lasting five nights.
  • Chronic Insomnia: Sustained effects were observed in a controlled sleep laboratory study lasting 28 nights.

Studies utilizing polysomnographic (sleep lab) measures have shown that quazepam may reduce sleep latency and total wake time. The medication and its long-acting active metabolites are hypothesized to work by modulating GABAA receptors in the central nervous system, enhancing the inhibitory effects of the neurotransmitter GABA.

Pharmacokinetics and Long-Term Context

Quazepam is rapidly absorbed, with a relatively long mean elimination half-life (approximately 39 hours for the parent drug and a major metabolite; up to 73 hours for a second major active metabolite). The persistence of these active metabolites may contribute to sustained effects on sleep and may be associated with residual effects during waking hours, such as daytime sedation or impaired motor function.

  • Long-Term Use: Clinical trials establishing efficacy and safety typically range from a few nights up to 4 weeks. Use beyond this duration is generally not recommended and carries an increased risk of tolerance, physical dependence, and withdrawal symptoms upon abrupt discontinuation.
  • Geriatric Populations: Studies suggest that older adults may be more sensitive to benzodiazepines. Special consideration is given to the prolonged elimination half-life of the active metabolites in this population.

Frequently Asked Questions (FAQ)

Common questions about Doral (FAQ)


Q: Is Doral the same as other medicines for the same condition?

Doral is a benzodiazepine-class medication used to assist with sleep. Official product information describes Doral as having a relatively long-acting profile, which is due to its major active metabolites. This characteristic contributes to a different profile when compared to some other hypnotics.


Q: How quickly does Doral start to work?

Official information indicates that the active ingredient in Doral, quazepam, is absorbed relatively quickly after administration. The drug’s highest concentration in the blood is typically reached about 1.75 hours after it is taken. Clinical studies have established its effect on sleep induction, which is the time needed to fall asleep.


Q: Does Doral cause confusion or 'fogginess' the next day?

Regulatory documents confirm that Doral is a central nervous system (CNS) depressant. Daytime drowsiness is a very common side effect that may persist into the day after use. This residual effect is officially described as impaired alertness and motor coordination, which patients may notice as 'fogginess' or residual impairment.


Q: Are the side effects of Doral temporary?

Due to the long half-life of Doral's active metabolites, residual effects such as daytime sedation and fatigue can persist into waking hours. Regulatory information suggests that the body may develop tolerance to some sedative effects over time. Information regarding side effects is covered in detail in the safety section of the official product labeling.


Q: Are there any specific foods or drinks to avoid while taking Doral?

Yes, official labeling specifies that alcohol generally should not be used concurrently with Doral. Combining alcohol and the medication can reinforce the central nervous system (CNS) depressant effects, increasing the potential for adverse reactions.


Q: Can Doral interact with over-the-counter pain relievers?

Official labeling documents that Doral may have additive effects when taken with other central nervous system (CNS) depressants. This is due to the potential for increased sedation and other effects. The labeling advises that the additive effects with other CNS depressants must be considered.


Q: Is it possible for Doral to interact with supplements like melatonin or CBD?

Official information notes that Doral is processed in the liver via certain enzyme systems, such as CYP3A4. Substances that affect these enzymes, including some herbal products, may change the amount of Doral in the body or enhance its CNS effects. While specific supplements are not explicitly named, the general risk of interaction with substances that affect these pathways is noted.


Q: Does Doral affect blood pressure?

Regulatory information indicates that low blood pressure (hypotension) may occur during therapeutic use, though this is not a common event. However, marked abnormalities in blood pressure, including hypertension or hypotension, can be noted during acute withdrawal from the medicine or in the context of an overdosage.


Q: What does 'clinical trial evidence' mean for Doral?

Clinical trial evidence for Doral comes from controlled studies, including sleep laboratory (polysomnographic) studies. This evidence demonstrates that the drug is effective in helping people fall asleep and in maintaining sleep by reducing the amount of time spent awake after sleep onset. This data is the foundation for the drug's approved indication.


Q: Does Doral interact with hormonal birth control?

Doral is subject to metabolism in the liver by the CYP3A4 enzyme system. Official documents warn that any substance that inhibits this enzyme system may increase the concentration of Doral in the bloodstream. The potential for interaction with specific medicines not listed should be discussed with a healthcare professional.


Q: Does Doral work the same way for everyone?

No, official labeling suggests that individual responses may vary. The regulatory documents specifically note that older adults and patients who are debilitated may be more sensitive to Doral's effects. Additionally, the long half-life of the drug's active metabolites can lead to different levels of residual daytime effects among individuals.


Q: What is the difference between Doral and over-the-counter sleep aids?

Doral is a prescription-only benzodiazepine derivative, formally classified as a Schedule IV controlled substance. Its primary action is through enhancing the inhibitory effect of the brain's GABA neurotransmitter. This mechanism and the drug's classification are different from the way most over-the-counter sleep aids function.


Q: Why does the label mention 'paradoxical reactions'?

The label contains warnings about 'Abnormal Thinking and Behavior Changes,' which may include unexpected reactions such as aggression, agitation, or worsening of depression. These types of opposite effects are often referred to as paradoxical reactions.


Q: Why do official sources sometimes use the term 'flurazepam'?

Flurazepam is another long-acting medication from the benzodiazepine class. Regulatory and authoritative clinical documents often use flurazepam as a point of comparison to help describe Doral's profile, particularly regarding its long half-life and potential for carry-over effects.

How should Doral be stored and disposed of?

How to Store and Dispose of Doral (Quazepam)

Storage Requirements

Doral tablets must be maintained at Controlled Room Temperature, officially defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept in a closed container and protected from excessive heat, freezing, moisture, and direct light.

Handling and Disposal

Doral is classified as a Schedule IV Controlled Substance, requiring it to be kept in a safe place and out of the reach of children to prevent misuse. Do not keep outdated or no longer needed medicine. Disposal of unused tablets must follow the specific safe disposal protocols established for controlled substances, such as using a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Doral found in:

A-Z Index: